Protocol
Exosome therapy
Exosomes · Extracellular vesicles (EVs) · Stem cell derived exosomes · Mesenchymal stem cell (MSC) exosomes · Stem cell culture supernatant · Conditioned media / secretome
Human data exist, but not for healthspan. The largest synthesis, a 2025 systematic review and meta-analysis of 39 human clinical studies in Aesthetic Surgery Journal, reports roughly 20% wrinkle reduction, 15-23% gains in pigmentation, elasticity and texture, and 18-24% improvements in hair density and thickness. Its own limitations are decisive: most included studies were open-label or single-arm, Cochrane ROB2 risk-of-bias assessment was "often not feasible", sample sizes were small and follow-up ran only 6-12 weeks. Every endpoint was surface dermatologic or trichologic. There are no systemic outcomes, no biomarkers of ageing, no organ-function or mortality data, and no controlled human trial of exosomes for any healthspan endpoint in either market. Systemic or IV exosome use for longevity is supported by mechanism and animal work only. Product characterisation is a second problem: "exosome" preparations are not standardised between suppliers, dose is not expressed in any comparable unit, and stem cell culture supernatant is a different and less defined material again. Safety is not neutral. A 2025 case series documents four women with persistent erythema, granulomatous nodules and permanent scarring after intradermal injection of cosmetic-grade exosome formulations, none of whom fully resolved despite steroids, laser and surgery. No exosome product holds marketing approval as a medicine in Australia, Singapore, the US or the EU. This should be presented as an aesthetic adjunct with early-stage cosmetic evidence, not as a systemic longevity protocol.
At a glance
- Evidence
- Commercial
- Singapore (HSA)
- No HSA position on file
- Australia (TGA)
- Not TGA-approved. Exosome and extracellular vesicle products fall under the TGA biologicals framework of the Therapeutic Goods Act 1989, and peer-reviewed analysis of the Australian regulatory landscape (Extracellular Vesicles and Circulating Nucleic Acids, 2025) confirms that of the 49 biological products on the ARTG as of April 2025, none are EV medicines. EVs from non-pluripotent stem cells would most likely be Class 3 biologicals, requiring a full non-clinical and clinical dossier. Lawful access to an unapproved exosome product is therefore only via a clinical trial, the Special Access Scheme (Category B) or the Authorised Prescriber scheme under s32CM, none of which are PBS-subsidised. Cosmetic-style topical add-on use as sold on aesthetic and longevity clinic menus sits outside any ARTG approval. Not verified: whether the TGA has issued exosome-specific enforcement action or a public advisory.
- Offered at
- 2 clinics
Singapore
Health Sciences Authority
- HSA status
- No position on file
- In our SG set
- Tracked in Singapore
- SG clinics
- 1
Australia
Therapeutic Goods Administration
- TGA status
- Not TGA-approved. Exosome and extracellular vesicle products fall under the TGA biologicals framework of the Therapeutic Goods Act 1989, and peer-reviewed analysis of the Australian regulatory landscape (Extracellular Vesicles and Circulating Nucleic Acids, 2025) confirms that of the 49 biological products on the ARTG as of April 2025, none are EV medicines. EVs from non-pluripotent stem cells would most likely be Class 3 biologicals, requiring a full non-clinical and clinical dossier. Lawful access to an unapproved exosome product is therefore only via a clinical trial, the Special Access Scheme (Category B) or the Authorised Prescriber scheme under s32CM, none of which are PBS-subsidised. Cosmetic-style topical add-on use as sold on aesthetic and longevity clinic menus sits outside any ARTG approval. Not verified: whether the TGA has issued exosome-specific enforcement action or a public advisory.
- In our AU set
- Tracked in Australia
- AU clinics
- 1
Evidence is not approvalAn evidence grade describes how strong the science is. A regulatory status describes whether a body has approved the intervention for an indication. They are different questions, answered separately above.
What it is
Plain-language explainer
Exosomes are nanoscale extracellular vesicles secreted by cells, most commonly harvested from cultured mesenchymal stem cells and supplied either as a purified vesicle preparation or as unfractionated "stem cell culture supernatant" (conditioned media). They carry proteins, lipids and RNA, and are marketed as a cell-free way to deliver regenerative signalling without transplanting live cells. In the Singapore and Australia longevity market they are sold almost entirely as an aesthetic adjunct: applied topically after microneedling or radiofrequency, or injected intradermally for skin and hair, and are claimed to speed recovery, improve skin quality and support hair regrowth.
Categories
Protocol
Offered by
Where variis has verified this protocol (2)
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- The regulatory landscape for extracellular vesicle therapies: Australian context and future directions · Extracellular Vesicles and Circulating Nucleic Acids (PMC)
- Australian Regulatory Guidelines for Biologicals (ARGB) · Therapeutic Goods Administration (TGA)
- Regulation of advanced therapies · Therapeutic Goods Administration (TGA)
- Regulatory overview of cell, tissue and gene therapy products · Health Sciences Authority (HSA), Singapore
- Regulatory overview of cosmetic products · Health Sciences Authority (HSA), Singapore
- Clinical Advances in Exosome-Based Therapies for Aesthetic Medicine: A Systematic Review and Meta-analysis of Human Clinical Trials · Aesthetic Surgery Journal (Oxford Academic)
- Exosomes and Hair Regeneration: A Systematic Review of Clinical Evidence Across Alopecia Types and Exosome Sources · Clinical, Cosmetic and Investigational Dermatology
- Adverse Reactions Following Intradermal Injection of Exosome-Based Formulations: A Case Series · PubMed Central
- Public Safety Notification on Exosome Products · US Food and Drug Administration
- Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes · US Food and Drug Administration
- Artisan Regenerative Centre services (lists Stem Cell Culture Supernatant) · Artisan Regenerative Centre
- Bespoke Longevity treatment menu (Add-on Exosomes with microneedling and hair regeneration) · Bespoke Longevity
Every entity profile on variis is sourced. Not medical advice.